Collect PBSC as in section 7.1. 
5 . Timing of Bone Marrow Harvests for Patients in 
Complete Remission/Chronic Phase 
At least 14 days after discontinuation of G-CSF 
and completion of PBSC collection, patients will 
undergo therapy with 5-FU. 
A pre-FU marrow aspirate and biopsy will be 
obtained to ensure adequate marrow cellularity 
(>30%) and to document continued remission/chronic 
phase. 5-FU administration will proceed only when 
marrow cellularity > 30%. Patients must have 
achieved a complete remission/return to chronic 
phase with one or two cycles of cytoreductive 
chemotherapy before proceeding to 5-FU treatment, 
marrow harvest and transplant. 
Bone marrow harvest will occur on day 10 after the 
first dose of 5-f luorouracil, and no later than 
day -5 prior to- transplantation (see below) . 
Marrow harvests will be delayed in patients who 
have not achieved an ANC of >1000/mm 3 or platelet 
count of > 100,000/mm 3 by day 10 post-FU. 
6 . 5-Fluorouracil Priming of Marrow : 
Patients will receive: 5-FU 15 mg/kg IV bolus QD x 
3 followed by marrow harvest 10 days later. 
Bone marrow aspirate and biopsy will be performed 
on day 5 and on day 15 following the initial dose 
of 5-f luorouracil to assess cellularity, 
progenitor content and retroviral infectivity. 
7 . Timing of Stem Cell fPeripheral Blood/Marrow) 
Transplant : 
Patients in accelerated phase, blast phase or > 
1st chronic phase will proceed to marrow 
transplant immediately. 
5 . 4 High-Dose Chemoradiotherapy and Transplant 
Throughout patients will receive standard antiemetic 
regimens as required, and intravenous hydration to 
maintain good urine output and normalize electrolytes. 
Day # 
[ 160 ] 
Recombinant DNA Research, Volume 16 
